TCF4 and colon adenocarcinoma: In contrast, colon adenocarcinoma showed a significant enrichment of TFs such as CDX2 (26.5%), CDX1 (24%), HOXA13 (22%), HNF4G (37.2%), and TCF4 (36%) in gained peaks; and FOS::JUNB (45.4%), FOS::JUND (47.5%) and JUNB (46.3%) in lost peaks.